Dengue vaccine gets green light for Indians aged 4-60 years

Takeda's two-dose QDENGA vaccine has been approved by the Drug Controller General of India for use in Indians aged 4-60 years. The vaccine is designed to protect against all four dengue virus serotypes and can be administered without prior dengue screening.

Reported by 2 sources

The Hindu — Science & Tech →The Hindu — Editorial →

Quick Revision

Prelims-testable facts

01The Drug Controller General of India has approved Takeda's two-dose QDENGA vaccine for individuals aged 4 to 60 years.
02Takeda's QDENGA vaccine is designed to protect against all four dengue virus serotypes.
03No prior dengue screening is required before administering the QDENGA vaccine.
04The QDENGA vaccine has been approved by the Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI).
05Takeda's QDENGA vaccine requires a two-dose regimen for protection against dengue virus serotypes.
06The QDENGA vaccine is manufactured locally with Biological E in collaboration with Takeda Pharmaceutical Company.
07A post-marketing study will be conducted to monitor the vaccine's effectiveness and safety.

Trap alerts

Most people think that the QDENGA vaccine requires prior dengue screening, but actually it does not.
Most people think that the QDENGA vaccine is only approved for individuals above 18 years of age, but actually it is approved for individuals aged 4 to 60 years.

Prelims Practice MCQs

Single facteasy

What is the age range for which Takeda's QDENGA vaccine has been approved?

A.2-18 years
B.4-60 years
C.9-25 years
D.12-45 years

The vaccine has been approved for use in Indians aged 4-60 years. This is a significant development in the fight against dengue fever.

Multiple statementsmedium

Consider the following statements regarding Takeda's QDENGA Vaccine Approval: 1. The Drug Controller General of India has approved Takeda's two-dose QDENGA vaccine for use in Indians aged 4-60 years. 2. Takeda's QDENGA vaccine is designed to protect against all four dengue virus serotypes and can be administered without prior dengue screening. 3. The Indian government has mandated a three-dose regimen of Takeda's QDENGA vaccine for its citizens. How many of the above statements are correct?

A.Only one
B.Only two
C.All three
D.None

Statement 1 is correct because fact #4 states that the vaccine is approved for use in Indians aged 4-60 years. Statement 2 is correct because fact #2 states that the vaccine is designed to protect against all four dengue virus serotypes and fact #3 states that it can be administered without prior dengue screening.

← All current affairs